CN113171452B - Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application - Google Patents

Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application Download PDF

Info

Publication number
CN113171452B
CN113171452B CN202110256221.5A CN202110256221A CN113171452B CN 113171452 B CN113171452 B CN 113171452B CN 202110256221 A CN202110256221 A CN 202110256221A CN 113171452 B CN113171452 B CN 113171452B
Authority
CN
China
Prior art keywords
nano
drug
iodized oil
preparation
homogeneous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110256221.5A
Other languages
Chinese (zh)
Other versions
CN113171452A (en
Inventor
刘刚
楚成超
代奇轩
许大壮
程红伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Priority to CN202110256221.5A priority Critical patent/CN113171452B/en
Publication of CN113171452A publication Critical patent/CN113171452A/en
Application granted granted Critical
Publication of CN113171452B publication Critical patent/CN113171452B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0625—Warming the body, e.g. hyperthermia treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a nano-drug iodized oil homogeneous phase preparation and a preparation method and application thereof. The nano-drug-iodized oil homogeneous preparation is a homogeneous preparation formed by uniformly dispersing a functional nano-drug in an iodized oil injection by using supercritical carbon dioxide, wherein the concentration of the functional nano-drug in the iodized oil is 0.1-20mg/mL; the functional nano-drug has magnetocaloric property or photo-thermal property, and is modified with oleic acid or oleylamine on the surface. The nano-drug-iodized oil homogeneous preparation has better dispersibility, and the nano-drug can be stably dispersed in the iodized oil without coagulation when being stored for a long time. After the nano-drug is introduced into the tumor region, the combined effect of embolization treatment and exogenous excitation heat radiation treatment can be realized.

Description

Nanometer medicinal preparation, iodized oil homogeneous preparation, and its preparation method and application
Technical Field
The invention relates to a nano-drug iodized oil homogeneous preparation, a preparation method thereof and application thereof in liver cancer embolism/thermal radiation combined treatment medicaments or embolization agents.
Background
In recent years, nanotechnology has become widely recognized by the public, and its special properties have enabled applications in still more disciplines. Meanwhile, the nano material is not only applied to a drug delivery system, but also widely applied to biological diagnosis and nano medical treatment due to excellent optical, electrical, magnetic, acoustic and other properties. At present, a plurality of nano-drugs are applied to clinical diagnosis and treatment and achieve better effects. However, the existing nano-drugs have the problems of low concentration of focus areas, in vivo toxicity, easy elimination by the immune system and the like. Therefore, a reasonable, efficient and safe nano-drug administration route is a scientific problem which needs to be solved urgently.
Under the imaging means, the means of introducing the medicament into the focus area through the catheter can realize the high-efficiency enrichment effect of the medicament. Furthermore, transcardial chemoembolization (TACE) is an important approach to liver cancer treatment. Iodophor oil (iodized oil) is widely used in TACE treatment of liver cancer due to its good tumor-selective deposition effect. The effective delivery of the nano-drug is realized while the iodized oil is used for embolism, and the synergy of TACE treatment and the nano-drug can be realized, so that the tumor treatment effect is enhanced. In 1994, mitsummori et al dispersed dextran-modified magnetic nanoparticles in iodized oil to obtain magnetofluid emulsion, and after the mixture embolization agent was introduced into tumor, combined therapeutic effect of embolization and magnetoheat was achieved (Mitsummori M, hiraoka M, shibata T, et al. Development of intra-atrial hyperthermia using a dextran-magnetic complex [ J]International journal of hyperthermia,1994,10 (6): 785-793). It has also been reported that Wangjianhua project group utilizes ultrasonic generator to convert Fe 3 O 4 The mixture prepared by dispersing the nano particles into the iodized oil retains Fe 3 O 4 The performance of the nano-particles as MRI contrast agent, and finally the iodized oil embolism heat treatment strategy realizes the treatment effect of the average tumor shrinkage of 8.1 percent after 14 days on a VX2 rabbit in-situ liver cancer model. The iodized oil is a slow deposition process in a tumor area, and the treatment effect can be well realized only by carrying out exogenous excited thermal radiation treatment after the iodized oil is deposited on the capillary vessels.
At present, the nano-drug is dispersed in the iodized oil through ultrasonic mixing to obtain an emulsion and a suspension, but heterogeneous coarse dispersion systems of the type are unstable in thermodynamics and kinetics, and after long-time embolism, the phenomenon that Brownian motion cannot be overcome when particles are large, the particles are subjected to gravity settling to generate a tendency of coalescence so as to reduce surface free energy, and then the particles are not dispersed. According to Stoke's law, the sedimentation velocity is in direct proportion to the radius of the particles and is in inverse proportion to the viscosity of the iodized oil, the overhigh viscosity of the iodized oil is not beneficial to the action of the medicine, the requirement on the form of the particles for reducing sedimentation is higher, and the modes of adding a deflocculant and the like are likely to influence the performance of the nano medicine or the dispersion medium, so that the dispersion medium cannot be continuously utilized. Therefore, the emulsion and suspension prepared by the prior art are easy to settle, and are not beneficial to the stimulation treatment after long-time embolism.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides a nano-drug iodized oil homogeneous preparation, a preparation method thereof and application thereof in liver cancer embolism/heat radiation combined treatment medicaments or embolization agents, solves the problem that long-time embolism is not beneficial to heat radiation combined treatment in the background art, and also solves the problem of continuous utilization of iodized oil.
One of the technical schemes adopted by the invention for solving the technical problems is as follows: provides a nano-drug-iodized oil homogeneous preparation, which is a homogeneous preparation formed by uniformly dispersing a functional nano-drug in an iodized oil injection by using supercritical carbon dioxide, wherein the concentration of the functional nano-drug in the iodized oil is 0.1-20mg/mL; the functional nano-drug has magnetocaloric property or photo-thermal property, and is modified with oleic acid or oleylamine on the surface.
In a preferred embodiment of the present invention, the particle size of the functional nano-drug is 10 to 500nm.
In a preferred embodiment of the present invention, the functional nano-drug with magnetocaloric properties is Fe 3 O 4 、MnFe 2 O 4 、Fe 2 O 3 One kind of (1).
In a preferred embodiment of the present invention, the functional nano-drug with photo-thermal properties is one of AuNPs, agNPs, ptNPs, graphene nanoplatelets, and carbon nanotubes.
In a preferred embodiment of the present invention, the functional nano-drug is one of nanospheres, nanorods, nanosheets and nanotubes.
In a preferred embodiment of the present invention, the specific gravity of the oleic acid or oleylamine in the functional nano-drug is 2 to 20wt%.
In a preferred embodiment of the present invention, the iodine oil injection is an iodine oil injection containing 37.0-41.0% iodine.
The second technical scheme adopted by the invention for solving the technical problems is as follows: provides a method for preparing a Nano-drug-iodized oil homogeneous phase preparation, namely a hyperstable homogeneous phase Nano-iodized oil formulation technology (SHIFT-Nano), which comprises the following steps:
1) Adding the iodine oil injection and the functional nano-drug into a high-pressure reaction kettle;
2) Injecting carbon dioxide into the high-pressure reaction kettle, pressurizing to 10-20 Mpa to form a supercritical environment, and continuously stirring for 1-2h;
3) After decompression, the nano-drug iodized oil homogeneous embolic agent is collected from the reaction kettle.
In a preferred embodiment of the present invention, in the step 1), the functional nano-drug is surface-modified by using oleate through pyrolysis or by using oleic acid as an additive solvent.
The third technical scheme adopted by the invention for solving the technical problems is as follows: provides an application of a nano-drug-iodized oil homogeneous preparation in a liver cancer embolism/heat radiation combined treatment medicament or an embolic agent.
Compared with the background technology, the technical scheme has the following advantages:
1. the invention carries out deep research on the delivery of Nano-drugs and provides a formula technology (SHIFT-Nano) of ultra-stable homogeneous Nano-iodine oil, the Nano-drugs are dispersed into the iodine oil by utilizing the supercritical carbon dioxide mixing preparation technology to obtain a homogeneous preparation, and compared with the existing heterogeneous preparations such as emulsion or suspension, the suppository prepared by the invention can not generate coagulation after standing for a long time; the homogeneous preparation is administrated to the tumor area in an intervention mode, so that the effective embolism treatment effect of the iodized oil can be realized, and the nano-drug is retained in the tumor tissue for a long time, so that the synergistic effect of thermal radiation treatment is realized under the condition of external excitation;
2. according to the invention, oleylamine or oleic acid is used for modifying the functional nano-drug, the dispersion of nano-particles in an oil phase is effectively improved, the specific gravity of oleic acid or oleylamine is 2% -20%, if the specific gravity of oleic acid or oleylamine is lower than 2%, the dispersion effect of the nano-drug in the oil phase is not ideal, and if the specific gravity of oleic acid or oleylamine is higher than 20%, the effective proportion of the drug is less, so that the therapeutic effect of the nano-drug is not facilitated;
3. the functional nano-drug is one of nanospheres, nanorods, nanosheets and nanotubes, has less requirements on the particles of the nano-drug and is easy to realize;
4. the photo-thermal and magneto-thermal treatment performance of the Nano-drug of the invention is not influenced after SHIFT-Nano operation, and the viscosity, solubility and diffusivity of iodized oil are not obviously influenced, so the Nano-drug can be continuously applied to the embolization treatment of liver cancer.
Drawings
FIG. 1 is a flow chart of a process for preparing a Nano-drug, namely an iodized oil homogeneous embolic agent by a SHIFT-Nano method;
FIG. 2 is a flow chart of the application of the nano-drug-iodized oil homogeneous embolic agent in the combined treatment of embolism;
FIG. 3 iodized oil (a), fe 3 O 4 Iodized oil homogeneous embolic agent (b) and Fe 3 O 4 -a change over time of the iodine oil suspension (b);
FIG. 4 iodine oil and Fe 3 O 4 -iodonium oil homogeneous embolic agent viscosity measurement;
FIG. 5 Water, iodized oil, fe 3 O 4 Aqueous solution and Fe 3 O 4 -temperature change of iodized oil homogeneous embolic agent under alternating magnetic field (10 kA/m,300 kHz).
Detailed Description
The invention will be more clearly illustrated by the following specific examples:
in the invention, through further research on the performance of the iodized oil, a technology for dispersing the Nano-drug with the surface modified by oleic acid or oleylamine into the iodized oil, which is hereinafter referred to as a ultrastable homogeneous Nano-iodized oil formula technology (SHIFT-Nano), is designed. The technology can disperse the nano-drug in the iodized oil for a long time, and simultaneously, the performance of the nano-drug cannot be influenced in the process. The iodized oil and the nano-drug can be embolized in the tumor region by means of interventional administration, so that embolization and nano-drug-based synergistic treatment are realized.
Example 1
1. This example is Fe 3 O 4 -a process for the preparation of a homogeneous formulation of iodonium oil comprising the following steps (figure 1):
(a) First, iron oleate complex is prepared by pretreatment, 5.4g FeCl 3 ·6H 2 O and 18.3g of sodium oleate were added to a mixed solution of 40mL of ethanol, 30mL of water and 70mL of hexane and reacted at 70 ℃ for 4 hours, thereby isolating an iron oleate complex; then adding iron oleate complex and oleic acid into 1-octadecene, wherein the addition amounts of the iron oleate complex, the oleic acid and the 1-octadecene are respectively 18g, 2.9g and 100g, and stably heating to 320 ℃ for 0.5h to obtain brownish black oleic acid surface modified Fe 3 O 4 A nanoparticle;
(b) 2mg of Fe are taken 3 O 4 Adding the nano particles and 2mL of iodized oil into a reaction kettle, injecting carbon dioxide into the reaction kettle, pressurizing to 20Mpa to form a supercritical environment, and continuously stirring for h;
(c) After depressurization, fe was collected from the reaction vessel 3 O 4 -iodooil homogeneous formulations.
2. Fe prepared in this example 3 O 4 -iodine oil homogeneous preparation, oleic acid modified Fe 3 O 4 The nanometer particles are uniformly dispersed in an iodized oil medium as a functional nanometer drug, and the embolic agent prepared based on the nanometer particles is applied to liver cancer embolism/heat radiation combined treatment and comprises the following steps:
(a) Mixing Fe 3 O 4 -an iodonium oil homogeneous embolic agent is introduced into the tumor tissue;
(b) The embolism effect is generated under the action of the iodized oil;
(c) And judging through various physiological indexes, and performing magnetic heat treatment by using an external magnetic heat device when the condition of the magnetic heat treatment is achieved.
Example 2
Example 2 differs from example 1 in that:
1. this example provides a method for preparing homogeneous embolic agent of AuNPs-iodized oil, comprising the following steps:
(a) Firstly, preparing AuNPs by utilizing chloroauric acid and sodium borohydride, adding the AuNPs and oleylamine which are prepared into ethanol according to the concentration of 2mg/mL and 1mg/mL, and stirring for 6 hours to obtain AuNPs nanoparticles with oleylamine surface modified;
(b) Adding 1mg of Fe3O4 nanoparticles and 2mL of iodized oil into a reaction kettle, injecting carbon dioxide into the reaction kettle, pressurizing to 15Mpa to form a supercritical environment, and continuously stirring for 1h;
(c) After decompression, the AuNPs-iodol homogeneous preparation was collected from the autoclave.
2. The embolism combined treatment based on the AuNPs-iodized oil homogeneous embolism agent comprises the following steps:
(a) Introducing AuNPs-iodized oil homogeneous embolic agent into tumor tissues;
(b) The embolism effect is generated under the action of the iodized oil;
(c) The judgment is carried out through various physiological indexes, and when the conditions of radiotherapy treatment are met, the photothermal treatment is carried out by utilizing an external photothermal device.
Subsequently, the Nano-drug-iodized oil homogeneous preparation prepared by the SHIFT-Nano method in the example and the Fe prepared by the traditional ultrasonic treatment for 30min 3 O 4 Iodine oil suspension as control, results are as follows:
Fe 3 O 4 iodine oil homogeneous embolic agent having specific Fe 3 O 4 Longer stabilization time of iodine oil suspensions (figure 3). And, fe after standing for 14 days 3 O 4 The iodized oil homogeneous embolic agent still has better dispersibility. In addition, the viscosity of the iodized oil is not influenced in the process of preparing the Nano medicament-iodized oil homogeneous embolic agent by using the SHIFT-Nano method (figure 4), thereby providing guarantee for subsequent embolic treatment.
Finally, for Fe 3 O 4 The magnetocaloric effect of the iodized oil homogeneous embolic agent was investigated. As shown in FIG. 5, fe 3 O 4 Iodine oil homogeneous embolic agent with Fe 3 O 4 Aqueous solutions have similar magnetocaloric effects. Thus, fe prepared 3 O 4 Lipiodol homogeneous embolization agents enable a combined effect of tumor embolization and magneto-caloric therapy.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.

Claims (4)

1. A method for preparing a nano-medicament-iodized oil homogeneous phase preparation is characterized by comprising the following steps: the nano-drug-iodized oil homogeneous preparation is a homogeneous preparation formed by uniformly dispersing a functional nano-drug in an iodized oil injection by using supercritical carbon dioxide, and the concentration of the functional nano-drug in the iodized oil is 0.1-20mg/mL; the functional nano-drug has magnetocaloric property or photo-thermal property, and is modified with oleic acid or oleylamine on the surface;
the preparation method comprises the following steps:
1) Adding the iodine oil injection and the functional nano-medicament into a high-pressure reaction kettle, wherein the functional nano-medicament is subjected to surface modification by using a method of decomposing oleate at high temperature or using oleic acid as an adding solvent;
2) Injecting carbon dioxide into the high-pressure reaction kettle, pressurizing to 10-20 Mpa to form a supercritical environment, and continuously stirring for 1-2h;
3) After decompression, collecting the nano-drug iodized oil homogeneous embolic agent from the reaction kettle;
the functional nano-drug with the magnetocaloric property is Fe 3 O 4 、MnFe 2 O 4 、Fe 2 O 3 One kind of (1).
2. The method for preparing the nano-drug-iodized oil homogeneous preparation according to claim 1, wherein the method comprises the following steps: the particle size of the functional nano-drug is 10-500 nm.
3. The method for preparing the nano-medicament-iodized oil homogeneous phase preparation according to claim 1, wherein the method comprises the following steps: the specific gravity of the oleic acid or the oleylamine in the functional nano-drug is 2-20 wt%.
4. The method for preparing the nano-drug-iodized oil homogeneous preparation according to claim 1, wherein the method comprises the following steps: the iodine oil injection is an iodine oil injection containing 37.0-41.0% of iodine.
CN202110256221.5A 2021-03-09 2021-03-09 Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application Active CN113171452B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110256221.5A CN113171452B (en) 2021-03-09 2021-03-09 Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110256221.5A CN113171452B (en) 2021-03-09 2021-03-09 Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application

Publications (2)

Publication Number Publication Date
CN113171452A CN113171452A (en) 2021-07-27
CN113171452B true CN113171452B (en) 2023-02-03

Family

ID=76921919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110256221.5A Active CN113171452B (en) 2021-03-09 2021-03-09 Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application

Country Status (1)

Country Link
CN (1) CN113171452B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952476A (en) * 2021-10-15 2022-01-21 厦门大学 Preparation of medicine-doped homogeneous phase ethanol chemical fusogenic agent

Also Published As

Publication number Publication date
CN113171452A (en) 2021-07-27

Similar Documents

Publication Publication Date Title
EP2010152B1 (en) Magnetic nanoparticles compositions and uses thereof
Lee et al. Paramagnetic inorganic nanoparticles as T1 MRI contrast agents
Khademi et al. Targeted gold nanoparticles enable molecular CT imaging of head and neck cancer: an in vivo study
CN110898234B (en) Two-dimensional bismuth nano composite material and preparation method and application thereof
CN107375928B (en) Preparation method and application of tumor targeted photothermal therapy nano-carrier
Zhang et al. All-in-one inorganic nanoagents for near-infrared-II photothermal-based cancer theranostics
CN113171452B (en) Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application
Li et al. Photogenerated electrons from CeO2 via upconversion of excitons to conduction band enhanced photocatalysis for Photo-Therapy of Rheumatoid arthritis
Lin et al. Size and morphological effect of Au–Fe 3 O 4 heterostructures on magnetic resonance imaging
Cai et al. Exfoliation and in situ functionalization of MoS2 nanosheets for MRI-guided combined low-temperature photothermal therapy and chemotherapy
Rivera et al. Biocompatible superparamagnetic carriers of chondroitin sulfate
Hu et al. Special interstitial route can transport nanoparticles to the brain bypassing the blood-brain barrier
Hu et al. Fe3O4 liposome for photothermal/chemo-synergistic inhibition of metastatic breast tumor
CN114533869A (en) Prussian blue @ mesoporous silica-perfluorohexane nanoparticle material and preparation method and application thereof
Li et al. Construction of WS2/Au-lipid drug delivery system for multiple combined therapy of tumor
Dozier et al. Synthesis of iron oxide nanoparticles with biological coatings
CN108671230A (en) A kind of gold nanoshell magnetism PLGA microcapsules and preparation method thereof
CN110538331B (en) Method for preparing magnetic nano-particles with improved dispersibility and particle uniformity
CN111773246A (en) Nano-composite capable of regulating and controlling iron apoptosis and immunotherapy as well as preparation and application thereof
Long et al. The story of ferumoxytol: synthesis production, current clinical applications, and therapeutic potential
CN113925968A (en) Multifunctional vanadium carbide/polydopamine nanosheet and preparation method and application thereof
CN113797226B (en) Ammonia borane/silicon sphere/mesoporous silica nano composite particle, preparation and application thereof
Yang et al. Combining hard and soft magnetism into a single core-shell nanoparticle to achieve both hyperthermia and image contrast
Hong et al. Bismuth-based two-dimensional nanomaterials for cancer diagnosis and treatment
CN116036270B (en) Preparation method and application of diagnosis and treatment integrated composite magnetic semiconductor nanomaterial

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant